Alzinova AB (publ) (“Alzinova” or the “Company”) is pleased to announce that the Company has strengthened its management team by appointing Sebastian Hansson as the new Business Development Director. In this newly created role, Sebastian will be instrumental in driving the strategic and operational work within Business Development for Alzinova.
Alzinova appoints Sebastian Hansson as new Business Development Director with responsibility for the continued business development that runs parallel to the further development of the Company's drug candidates ALZ-101 and ALZ-201. Sebastian holds a PhD in molecular biophysics and an MBA. He has 15 years of experience in drug development, CRO and GMP production of pharmaceutical compounds. Sebastian comes most recently from a position as Chief Operating Officer, COO at SWIPP.
“I am very pleased to appoint Sebastian Hansson as the new Business Development Director for Alzinova. Sebastian will be a valuable asset to our management team and in driving the strategic and operational work within Business Development. Sebastian brings many years of solid experience in the pharmaceutical industry, most recently as COO at SWIPP”, says Kristina Torfgård, CEO of Alzinova.
“I am delighted to have been entrusted to lead the business development of Alzinova - an exciting company with great potential to become a leading player in the development of treatments for Alzheimer's disease. I look forward to top-line data from the ongoing clinical trial and using this to drive value and interest from potential partners. This in turn will allow us to build the Company further and develop our partnering activities", says Sebastian Hansson, Business Development Director for Alzinova.
ALZINOVA AB 